Recent submissions

  • Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition 

    Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; Miranda, S; Perez-Lopez, R; Dolling, D; Robinson, D; Sandhu, S; Fowler, G; Ebbs, B; Flohr, P; Seed, G; Nava Rodrigues, D; Boysen, G; Bertan, C; Atkin, M; Crespo, M; Figueiredo, I; Riisnaes, R; Sumanasuriya, S; Rescigno, P; Zafeiriou, Z; Tunariu, N; Bianchini, D; Gillman, A; Lord, C; Hall, E; Chinnaiyan, A; Carreira, S; De Bono, J
  • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. 

    Phelan, CM; Kuchenbaecker, KB; Tyrer, JP; Kar, SP; Lawrenson, K; Winham, SJ; Dennis, J; Pirie, A; Riggan, MJ; Chornokur, G; Earp, MA; Lyra, PC; Lee, JM; Coetzee, S; Beesley, J; McGuffog, L; Soucy, P; Dicks, E; Lee, A; Barrowdale, D; Lecarpentier, J; Leslie, G; Aalfs, CM; Aben, KKH; Adams, M; Adlard, J; Andrulis, IL; Anton-Culver, H; Antonenkova, N; AOCS study group; Aravantinos, G; Arnold, N; Arun, BK; Arver, B; Azzollini, J; Balmaña, J; Banerjee, SN; Barjhoux, L; Barkardottir, RB; Bean, Y; Beckmann, MW; Beeghly-Fadiel, A; Benitez, J; Bermisheva, M; Bernardini, MQ; Birrer, MJ; Bjorge, L; Black, A; Blankstein, K; Blok, MJ; Bodelon, C; Bogdanova, N; Bojesen, A; Bonanni, B; Borg, Å; Bradbury, AR; Brenton, JD; Brewer, C; Brinton, L; Broberg, P; Brooks-Wilson, A; Bruinsma, F; Brunet, J; Buecher, B; Butzow, R; Buys, SS; Caldes, T; Caligo, MA; Campbell, I; Cannioto, R; Carney, ME; Cescon, T; Chan, SB; Chang-Claude, J; Chanock, S; Chen, XQ; Chiew, YE; Chiquette, J; Chung, WK; Claes, KBM; Conner, T; Cook, LS; Cook, J; Cramer, DW; Cunningham, JM; D'Aloisio, AA; Daly, MB; Damiola, F; Damirovna, SD; Dansonka-Mieszkowska, A; Dao, F; Davidson, R; DeFazio, A; Delnatte, C; Doheny, KF; Diez, O; Ding, YC; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Dossus, L; Duran, M; Dürst, M; Dworniczak, B; Eccles, D; Edwards, T; Eeles, R; Eilber, U; Ejlertsen, B; Ekici, AB; Ellis, S; Elvira, M; EMBRACE Study; Eng, KH; Engel, C; Evans, DG; Fasching, PA; Ferguson, S; Ferrer, SF; Flanagan, JM; Fogarty, ZC; Fortner, RT; Fostira, F; Foulkes, WD; Fountzilas, G; Fridley, BL; Friebel, TM; Friedman, E; Frost, D; Ganz, PA; Garber, J; García, MJ; Garcia-Barberan, V; Gehrig, A; GEMO Study Collaborators; Gentry-Maharaj, A; Gerdes, AM; Giles, GG; Glasspool, R; Glendon, G; Godwin, AK; Goldgar, DE; Goranova, T; Gore, M; Greene, MH; Gronwald, J; Gruber, S; Hahnen, E; Haiman, CA; Håkansson, N; Hamann, U; Hansen, TVO; Harrington, PA; Harris, HR; Hauke, J; HEBON Study; Hein, A; Henderson, A; Hildebrandt, MAT; Hillemanns, P; Hodgson, S; Høgdall, CK; Høgdall, E; Hogervorst, FBL; Holland, H; Hooning, MJ; Hosking, K; Huang, RY; Hulick, PJ; Hung, J; Hunter, DJ; Huntsman, DG; Huzarski, T; Imyanitov, EN; Isaacs, C; Iversen, ES; Izatt, L; Izquierdo, A; Jakubowska, A; James, P; Janavicius, R; Jernetz, M; Jensen, A; Jensen, UB; John, EM; Johnatty, S; Jones, ME; Kannisto, P; Karlan, BY; Karnezis, A; Kast, K; KConFab Investigators; Kennedy, CJ; Khusnutdinova, E; Kiemeney, LA; Kiiski, JI; Kim, SW; Kjaer, SK; Köbel, M; Kopperud, RK; Kruse, TA; Kupryjanczyk, J; Kwong, A; Laitman, Y; Lambrechts, D; Larrañaga, N; Larson, MC; Lazaro, C; Le, ND; Le Marchand, L; Lee, JW; Lele, SB; Leminen, A; Leroux, D; Lester, J; Lesueur, F; Levine, DA; Liang, D; Liebrich, C; Lilyquist, J; Lipworth, L; Lissowska, J; Lu, KH; Lubinński, J; Luccarini, C; Lundvall, L; Mai, PL; Mendoza-Fandiño, G; Manoukian, S; Massuger, LFAG; May, T; Mazoyer, S; McAlpine, JN; McGuire, V; McLaughlin, JR; McNeish, I; Meijers-Heijboer, H; Meindl, A; Menon, U; Mensenkamp, AR; Merritt, MA; Milne, RL; Mitchell, G; Modugno, F; Moes-Sosnowska, J; Moffitt, M; Montagna, M; Moysich, KB; Mulligan, AM; Musinsky, J; Nathanson, KL; Nedergaard, L; Ness, RB; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Nussbaum, RL; Odunsi, K; Olah, E; Olopade, OI; Olsson, H; Olswold, C; O'Malley, DM; Ong, KR; Onland-Moret, NC; OPAL study group; Orr, N; Orsulic, S; Osorio, A; Palli, D; Papi, L; Park-Simon, TW; Paul, J; Pearce, CL; Pedersen, IS; Peeters, PHM; Peissel, B; Peixoto, A; Pejovic, T; Pelttari, LM; Permuth, JB; Peterlongo, P; Pezzani, L; Pfeiler, G; Phillips, KA; Piedmonte, M; Pike, MC; Piskorz, AM; Poblete, SR; Pocza, T; Poole, EM; Poppe, B; Porteous, ME; Prieur, F; Prokofyeva, D; Pugh, E; Pujana, MA; Pujol, P; Radice, P; Rantala, J; Rappaport-Fuerhauser, C; Rennert, G; Rhiem, K; Rice, P; Richardson, A; Robson, M; Rodriguez, GC; Rodríguez-Antona, C; Romm, J; Rookus, MA; Rossing, MA; Rothstein, JH; Rudolph, A; Runnebaum, IB; Salvesen, HB; Sandler, DP; Schoemaker, MJ; Senter, L; Setiawan, VW; Severi, G; Sharma, P; Shelford, T; Siddiqui, N; Side, LE; Sieh, W; Singer, CF; Sobol, H; Song, H; Southey, MC; Spurdle, AB; Stadler, Z; Steinemann, D; Stoppa-Lyonnet, D; Sucheston-Campbell, LE; Sukiennicki, G; Sutphen, R; Sutter, C; Swerdlow, AJ; Szabo, CI; Szafron, L; Tan, YY; Taylor, JA; Tea, MK; Teixeira, MR; Teo, SH; Terry, KL; Thompson, PJ; Thomsen, LCV; Thull, DL; Tihomirova, L; Tinker, AV; Tischkowitz, M; Tognazzo, S; Toland, AE; Tone, A; Trabert, B; Travis, RC; Trichopoulou, A; Tung, N; Tworoger, SS; van Altena, AM; Van Den Berg, D; van der Hout, AH; van der Luijt, RB; Van Heetvelde, M; Van Nieuwenhuysen, E; van Rensburg, EJ; Vanderstichele, A; Varon-Mateeva, R; Vega, A; Edwards, DV; Vergote, I; Vierkant, RA; Vijai, J; Vratimos, A; Walker, L; Walsh, C; Wand, D; Wang-Gohrke, S; Wappenschmidt, B; Webb, PM; Weinberg, CR; Weitzel, JN; Wentzensen, N; Whittemore, AS; Wijnen, JT; Wilkens, LR; Wolk, A; Woo, M; Wu, X; Wu, AH; Yang, H; Yannoukakos, D; Ziogas, A; Zorn, KK; Narod, SA; Easton, DF; Amos, CI; Schildkraut, JM; Ramus, SJ; Ottini, L; Goodman, MT; Park, SK; Kelemen, LE; Risch, HA; Thomassen, M; Offit, K; Simard, J; Schmutzler, RK; Hazelett, D; Monteiro, AN; Couch, FJ; Berchuck, A; Chenevix-Trench, G; Goode, EL; Sellers, TA; Gayther, SA; Antoniou, AC; Pharoah, PDP (2017-03-27)
    To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified ...
  • Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy. 

    Faisal, A; Mak, GW; Gurden, MD; Xavier, CP; Anderhub, SJ; Innocenti, P; Westwood, IM; Naud, S; Hayes, A; Box, G; Valenti, MR; De Haven Brandon, AK; O'Fee, L; Schmitt, J; Woodward, HL; Burke, R; vanMontfort, RL; Blagg, J; Raynaud, FI; Eccles, SA; Hoelder, S; Linardopoulos, S (2017-03-23)
    BACKGROUND: The main role of the cell cycle is to enable error-free DNA replication, chromosome segregation and cytokinesis. One of the best characterised checkpoint pathways is the spindle assembly checkpoint, which ...
  • Ultrasound Tomography Evaluation of Breast Density: A Comparison With Noncontrast Magnetic Resonance Imaging. 

    OʼFlynn, EA; Fromageau, J; Ledger, AE; Messa, A; DʼAquino, A; Schoemaker, MJ; Schmidt, M; Duric, N; Swerdlow, AJ; Bamber, JC (2017-01-24)
    OBJECTIVES: Ultrasound tomography (UST) is an emerging whole-breast 3-dimensional imaging technique that obtains quantitative tomograms of speed of sound of the entire breast. The imaged parameter is the speed of sound ...
  • Advances and challenges in targeting FGFR signalling in cancer. 

    Babina, IS; Turner, NC (2017-05)
    Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes. Deregulation of FGFR signalling is observed in a subset of many cancers, making activated FGFRs a highly promising potential ...
  • PARP inhibitors: Synthetic lethality in the clinic. 

    Lord, CJ; Ashworth, A (2017-03-17)
    PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a century ago. Tumors ...
  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 

    Hollestelle, A; van der Baan, FH; Berchuck, A; Johnatty, SE; Aben, KK; Agnarsson, BA; Aittomäki, K; Alducci, E; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Antoniou, AC; Apicella, C; Arndt, V; Arnold, N; Arun, BK; Arver, B; Ashworth, A; Baglietto, L; Balleine, R; Bandera, EV; Barrowdale, D; Bean, YT; Beckmann, L; Beckmann, MW; Benitez, J; Berger, A; Berger, R; Beuselinck, B; Bisogna, M; Bjorge, L; Blomqvist, C; Bogdanova, NV; Bojesen, A; Bojesen, SE; Bolla, MK; Bonanni, B; Brand, JS; Brauch, H; Brenner, H; Brinton, L; Brooks-Wilson, A; Bruinsma, F; Brunet, J; Brüning, T; Budzilowska, A; Bunker, CH; Burwinkel, B; Butzow, R; Buys, SS; Caligo, MA; Campbell, I; Carter, J; Chang-Claude, J; Chanock, SJ; Claes, KB; Collée, JM; Cook, LS; Couch, FJ; Cox, A; Cramer, D; Cross, SS; Cunningham, JM; Cybulski, C; Czene, K; Damiola, F; Dansonka-Mieszkowska, A; Darabi, H; de la Hoya, M; deFazio, A; Dennis, J; Devilee, P; Dicks, EM; Diez, O; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Silva, IS; du Bois, A; Dumont, M; Dunning, AM; Duran, M; Easton, DF; Eccles, D; Edwards, RP; Ehrencrona, H; Ejlertsen, B; Ekici, AB; Ellis, SD; Engel, C; Eriksson, M; Fasching, PA; Feliubadalo, L; Figueroa, J; Flesch-Janys, D; Fletcher, O; Fontaine, A; Fortuzzi, S; Fostira, F; Fridley, BL; Friebel, T; Friedman, E; Friel, G; Frost, D; Garber, J; García-Closas, M; Gayther, SA; Gentry-Maharaj, A; Gerdes, AM; Giles, GG; Glasspool, R; Glendon, G; Godwin, AK; Goodman, MT; Gore, M; Greene, MH; Grip, M; Gronwald, J; Gschwantler Kaulich, D; Guénel, P; Guzman, SR; Haeberle, L; Haiman, CA; Hall, P; Halverson, SL; Hamann, U; Hansen, TV; Harter, P; Hartikainen, JM; Healey, S; Hein, A; Heitz, F; Henderson, BE; Herzog, J; T Hildebrandt, MA; Høgdall, CK; Høgdall, E; Hogervorst, FB; Hopper, JL; Humphreys, K; Huzarski, T; Imyanitov, EN; Isaacs, C; Jakubowska, A; Janavicius, R; Jaworska, K; Jensen, A; Jensen, UB; Johnson, N; Jukkola-Vuorinen, A; Kabisch, M; Karlan, BY; Kataja, V; Kauff, N; Kelemen, LE; Kerin, MJ; Kiemeney, LA; Kjaer, SK; Knight, JA; Knol-Bout, JP; Konstantopoulou, I; Kosma, VM; Krakstad, C; Kristensen, V; Kuchenbaecker, KB; Kupryjanczyk, J; Laitman, Y; Lambrechts, D; Lambrechts, S; Larson, MC; Lasa, A; Laurent-Puig, P; Lazaro, C; Le, ND; Le Marchand, L; Leminen, A; Lester, J; Levine, DA; Li, J; Liang, D; Lindblom, A; Lindor, N; Lissowska, J; Long, J; Lu, KH; Lubinski, J; Lundvall, L; Lurie, G; Mai, PL; Mannermaa, A; Margolin, S; Mariette, F; Marme, F; Martens, JW; Massuger, LF; Maugard, C; Mazoyer, S; McGuffog, L; McGuire, V; McLean, C; McNeish, I; Meindl, A; Menegaux, F; Menéndez, P; Menkiszak, J; Menon, U; Mensenkamp, AR; Miller, N; Milne, RL; Modugno, F; Montagna, M; Moysich, KB; Müller, H; Mulligan, AM; Muranen, TA; Narod, SA; Nathanson, KL; Ness, RB; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, FC; Nielsen, SF; Nordestgaard, BG; Nussbaum, RL; Odunsi, K; Offit, K; Olah, E; Olopade, OI; Olson, JE; Olson, SH; Oosterwijk, JC; Orlow, I; Orr, N; Orsulic, S; Osorio, A; Ottini, L; Paul, J; Pearce, CL; Pedersen, IS; Peissel, B; Pejovic, T; Pelttari, LM; Perkins, J; Permuth-Wey, J; Peterlongo, P; Peto, J; Phelan, CM; Phillips, KA; Piedmonte, M; Pike, MC; Platte, R; Plisiecka-Halasa, J; Poole, EM; Poppe, B; Pylkäs, K; Radice, P; Ramus, SJ; Rebbeck, TR; Reed, MW; Rennert, G; Risch, HA; Robson, M; Rodriguez, GC; Romero, A; Rossing, MA; Rothstein, JH; Rudolph, A; Runnebaum, I; Salani, R; Salvesen, HB; Sawyer, EJ; Schildkraut, JM; Schmidt, MK; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schrauder, MG; Schumacher, F; Schwaab, I; Scuvera, G; Sellers, TA; Severi, G; Seynaeve, CM; Shah, M; Shrubsole, M; Siddiqui, N; Sieh, W; Simard, J; Singer, CF; Sinilnikova, OM; Smeets, D; Sohn, C; Soller, M; Song, H; Soucy, P; Southey, MC; Stegmaier, C; Stoppa-Lyonnet, D; Sucheston, L; Swerdlow, A; Tangen, IL; Tea, MK; Teixeira, MR; Terry, KL; Terry, MB; Thomassen, M; Thompson, PJ; Tihomirova, L; Tischkowitz, M; Toland, AE; Tollenaar, RA; Tomlinson, I; Torres, D; Truong, T; Tsimiklis, H; Tung, N; Tworoger, SS; Tyrer, JP; Vachon, CM; Van 't Veer, LJ; van Altena, AM; Van Asperen, CJ; van den Berg, D; van den Ouweland, AM; van Doorn, HC; Van Nieuwenhuysen, E; van Rensburg, EJ; Vergote, I; Verhoef, S; Vierkant, RA; Vijai, J; Vitonis, AF; von Wachenfeldt, A; Walsh, C; Wang, Q; Wang-Gohrke, S; Wappenschmidt, B; Weischer, M; Weitzel, JN; Weltens, C; Wentzensen, N; Whittemore, AS; Wilkens, LR; Winqvist, R; Wu, AH; Wu, X; Yang, HP; Zaffaroni, D; Pilar Zamora, M; Zheng, W; Ziogas, A; Chenevix-Trench, G; Pharoah, PD; Rookus, MA; Hooning, MJ; Goode, EL (2016-05)
    Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well ...
  • PARP inhibitor combination therapy. 

    Dréan, A; Lord, CJ; Ashworth, A (2016-12)
    In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with ...
  • Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. 

    Wentzensen, N; Poole, EM; Trabert, B; White, E; Arslan, AA; Patel, AV; Setiawan, VW; Visvanathan, K; Weiderpass, E; Adami, HO; Black, A; Bernstein, L; Brinton, LA; Buring, J; Butler, LM; Chamosa, S; Clendenen, TV; Dossus, L; Fortner, R; Gapstur, SM; Gaudet, MM; Gram, IT; Hartge, P; Hoffman-Bolton, J; Idahl, A; Jones, M; Kaaks, R; Kirsh, V; Koh, WP; Lacey, JV; Lee, IM; Lundin, E; Merritt, MA; Onland-Moret, NC; Peters, U; Poynter, JN; Rinaldi, S; Robien, K; Rohan, T; Sandler, DP; Schairer, C; Schouten, LJ; Sjöholm, LK; Sieri, S; Swerdlow, A; Tjonneland, A; Travis, R; Trichopoulou, A; van den Brandt, PA; Wilkens, L; Wolk, A; Yang, HP; Zeleniuch-Jacquotte, A; Tworoger, SS (2016-08)
    An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle factors by histologic ...
  • The regulatory isoform rPGRP-LC induces immune resolution via endosomal degradation of receptors 

    Neyen, C; Runchel, C; Schüpfer, F; Meier, P; Lemaitre, B (2016-08-22)
  • Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma. 

    Smyth, EC; Babina, IS; Turner, NC (2017-03)
    FGFR2 genetic translocations are frequent in cholangiocarcinoma, yet despite initial sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted therapies. The work published by Goyal and ...
  • BRCA2 hypomorphic missense variants confer moderate risks of breast cancer. 

    Shimelis, H; Mesman, RL; Von Nicolai, C; Ehlen, A; Guidugli, L; Martin, C; Calleja, FM; Meeks, H; Hallberg, E; Hinton, J; Lilyquist, J; Hu, C; Aalfs, CM; Aittomaki, K; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Benitez, JJ; Bogdanova, N; Bojesen, SE; Bolla, MK; Borresen-Dale, AL; Brauch, H; Brennan, P; Brenner, H; Broeks, A; Brouwers, B; Bruning, T; Burwinkel, B; Chang-Claude, J; Chenevix-Trench, G; Cheng, CY; Choi, JY; Collée, JM; Cox, A; Cross, SS; Czene, K; Darabi, H; Dennis, J; Dork, T; Dos Santos Silva, I; Dunning, AM; Fasching, PA; Figueroa, JD; Flyger, H; Garcia-Closas, M; Giles, GG; Glendon, G; Guenel, P; Haiman, CA; Hall, P; Hamann, U; Hartman, M; Hogervorst, FB; Hollestelle, A; Hopper, JL; Ito, H; Jakubowska, A; Kang, D; Kosma, VM; Kristensen, V; Lai, KN; Lambrechts, D; Le Marchand, L; Li, J; Lindblom, A; Lophatananon, A; Lubinski, J; Machackova, E; Mannermaa, A; Margolin, S; Marme, F; Matsuo, K; Miao, H; Michailidou, K; Milne, RL; Muir, K; Neuhausen, SL; Nevanlinna, H; Olson, JE; Olswold, C; Oosterwijk, JC; Osorio, A; Peterlongo, P; Peto, J; Pharoah, PD; Pylkäs, K; Radice, P; Rashid, MU; Rhenius, V; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schoemaker, MJ; Seynaeve, CM; Shah, M; Shen, CY; Shrubsole, MJ; Shu, XO; Slager, SL; Southey, MC; Stram, DO; Swerdlow, AJ; Teo, SH; Tomlinson, I; Torres, D; Truong, T; van Asperen, CJ; van der Kolk, LE; Wang, Q; Winqvist, R; Wu, AH; Yu, JC; Zheng, W; Zheng, Y; Leary, J; Walker, LC; Foretova, L; Fostira, F; Claes, K; Varesco, L; Moghadasi, S; Easton, DF; Spurdle, AB; Devilee, P; Vrieling, H; Monteiro, AN; Goldgar, DE; Carreira, A; Vreeswijk, MP; Couch, FJ (2017-03-10)
    Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often referred to as variants of uncertain significance (VUS), have not been established. In this study, associations between ...
  • Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures 

    Morrison, E; Wai, P; Leonidou, A; Bland, P; Khalique, S; Farnie, G; Daley, F; Peck, B; Natrajan, R (2016)
  • Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (vol 76, pg 2301, 2016) 

    Herrera-Abreu, MT; Palafox, M; Asghar, U; Rivas, MA; Cutts, RJ; Garcia-Murillas, I; Pearson, A; Guzman, M; Rodriguez, O; Grueso, J; Bellet, M; Cortes, J; Elliott, R; Pancholi, S; Lord, CJ; Baselga, J; Dowsett, M; Martin, L-A; Turner, NC; Serra, V (2016-10)
  • The Controlling Cancer Summit, 17-19 May 2016, London, UK. 

    Babina, IS (2016-10)
    The Controlling Cancer Summit, London, UK, 17-19 May 2016 The Controlling Cancer Summit is an intimate informal meeting that annually gathers international academic and clinical researchers to network and debate the current ...
  • LAUNCH OF THE BREAST SCREENING AFTER RADIOTHERAPY DATASET - AN ENGLAND WIDE INITIATIVE TO IMPROVE SCREENING FOR BREAST CANCER IN 9,000 WOMEN AT HIGH RISK FOLLOWING RADIOTHERAPY TO BREAST TISSUE UNDER AGE 36 

    Radford, J; Howell, S; Vaughan, K; Goode, V; Worthington, D; Yates-Bolton, N; Payne, E; Jenkins, J; Sibbering, M; Swerdlow, A; Cowan, R (2016-10)
  • Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. 

    Detre, SI; Ashley, S; Mohammed, K; Smith, IE; Powles, TJ; Dowsett, M (2017-03)
    The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (n = 2,471) were randomly assigned to tamoxifen ...
  • Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. 

    Zeng, C; Guo, X; Long, J; Kuchenbaecker, KB; Droit, A; Michailidou, K; Ghoussaini, M; Kar, S; Freeman, A; Hopper, JL; Milne, RL; Bolla, MK; Wang, Q; Dennis, J; Agata, S; Ahmed, S; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arason, A; Arndt, V; Arun, BK; Arver, B; Bacot, F; Barrowdale, D; Baynes, C; Beeghly-Fadiel, A; Benitez, J; Bermisheva, M; Blomqvist, C; Blot, WJ; Bogdanova, NV; Bojesen, SE; Bonanni, B; Borresen-Dale, AL; Brand, JS; Brauch, H; Brennan, P; Brenner, H; Broeks, A; Brüning, T; Burwinkel, B; Buys, SS; Cai, Q; Caldes, T; Campbell, I; Carpenter, J; Chang-Claude, J; Choi, JY; Claes, KB; Clarke, C; Cox, A; Cross, SS; Czene, K; Daly, MB; de la Hoya, M; De Leeneer, K; Devilee, P; Diez, O; Domchek, SM; Doody, M; Dorfling, CM; Dörk, T; Dos-Santos-Silva, I; Dumont, M; Dwek, M; Dworniczak, B; Egan, K; Eilber, U; Einbeigi, Z; Ejlertsen, B; Ellis, S; Frost, D; Lalloo, F; Fasching, PA; Figueroa, J; Flyger, H; Friedlander, M; Friedman, E; Gambino, G; Gao, YT; Garber, J; García-Closas, M; Gehrig, A; Damiola, F; Lesueur, F; Mazoyer, S; Stoppa-Lyonnet, D; Giles, GG; Godwin, AK; Goldgar, DE; González-Neira, A; Greene, MH; Guénel, P; Haeberle, L; Haiman, CA; Hallberg, E; Hamann, U; Hansen, TV; Hart, S; Hartikainen, JM; Hartman, M; Hassan, N; Healey, S; Hogervorst, FB; Verhoef, S; Hendricks, CB; Hillemanns, P; Hollestelle, A; Hulick, PJ; Hunter, DJ; Imyanitov, EN; Isaacs, C; Ito, H; Jakubowska, A; Janavicius, R; Jaworska-Bieniek, K; Jensen, UB; John, EM; Joly Beauparlant, C; Jones, M; Kabisch, M; Kang, D; Karlan, BY; Kauppila, S; Kerin, MJ; Khan, S; Khusnutdinova, E; Knight, JA; Konstantopoulou, I; Kraft, P; Kwong, A; Laitman, Y; Lambrechts, D; Lazaro, C; Le Marchand, L; Lee, CN; Lee, MH; Lester, J; Li, J; Liljegren, A; Lindblom, A; Lophatananon, A; Lubinski, J; Mai, PL; Mannermaa, A; Manoukian, S; Margolin, S; Marme, F; Matsuo, K; McGuffog, L; Meindl, A; Menegaux, F; Montagna, M; Muir, K; Mulligan, AM; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Newcomb, PA; Nord, S; Nussbaum, RL; Offit, K; Olah, E; Olopade, OI; Olswold, C; Osorio, A; Papi, L; Park-Simon, TW; Paulsson-Karlsson, Y; Peeters, S; Peissel, B; Peterlongo, P; Peto, J; Pfeiler, G; Phelan, CM; Presneau, N; Radice, P; Rahman, N; Ramus, SJ; Rashid, MU; Rennert, G; Rhiem, K; Rudolph, A; Salani, R; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Schoemaker, MJ; Schürmann, P; Seynaeve, C; Shen, CY; Shrubsole, MJ; Shu, XO; Sigurdson, A; Singer, CF; Slager, S; Soucy, P; Southey, M; Steinemann, D; Swerdlow, A; Szabo, CI; Tchatchou, S; Teixeira, MR; Teo, SH; Terry, MB; Tessier, DC; Teulé, A; Thomassen, M; Tihomirova, L; Tischkowitz, M; Toland, AE; Tung, N; Turnbull, C; van den Ouweland, AM; van Rensburg, EJ; Ven den Berg, D; Vijai, J; Wang-Gohrke, S; Weitzel, JN; Whittemore, AS; Winqvist, R; Wong, TY; Wu, AH; Yannoukakos, D; Yu, JC; Pharoah, PD; Hall, P; Chenevix-Trench, G; Dunning, AM; Simard, J; Couch, FJ; Antoniou, AC; Easton, DF; Zheng, W (2016-01)
    Multiple recent genome-wide association studies (GWAS) have identified a single nucleotide polymorphism (SNP), rs10771399, at 12p11 that is associated with breast cancer risk.We performed a fine-scale mapping study of a ...
  • Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma. 

    Beck, D; Zobel, J; Barber, R; Evans, S; Lezina, L; Allchin, RL; Blades, M; Elliott, R; Lord, CJ; Ashworth, A; Porter, AC; Wagner, SD (2016-08)
    We demonstrate the usefulness of synthetic lethal screening of a conditionally BCL6-deficient Burkitt lymphoma cell line, DG75-AB7, with a library of small molecules to determine survival pathways suppressed by BCL6 and ...

View more